董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vickie Capps | 女 | Director | 57 | 未披露 | 未持股 | 2018-10-31 |
| Floyd Romesberg | 男 | Director | 52 | 未披露 | 未持股 | 2018-10-31 |
| Jay Lichter | 男 | Chairman of the Board of Director | 56 | 未披露 | 未持股 | 2018-10-31 |
| Peter Thompson | 男 | Director | 59 | 未披露 | 未持股 | 2018-10-31 |
| Laura Shawver | 女 | President, Chief Executive Officer and Director | 61 | 15.12万美元 | 未持股 | 2018-10-31 |
| Pratik Shah | 男 | Director | 49 | 未披露 | 未持股 | 2018-10-31 |
| Peter Kolchinsky | 男 | Director | 42 | 未披露 | 未持股 | 2018-10-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Leveque | 男 | Chief Medical Officer | 58 | 未披露 | 未持股 | 2018-10-31 |
| Tighe Reardon | 男 | Acting Chief Financial Officer | 42 | 未披露 | 未持股 | 2018-10-31 |
| Marcos Milla | 男 | Chief Scientific Officer | 55 | 22.26万美元 | 未持股 | 2018-10-31 |
| Laura Shawver | 女 | President, Chief Executive Officer and Director | 61 | 15.12万美元 | 未持股 | 2018-10-31 |
董事简历
中英对照 | 中文 | 英文- Vickie Capps
-
Vickie Capps自2021年3月起担任Janux Therapeutics, Inc.的董事会成员。Vickie Capps从2002年7月到2013年12月，担任DJO Global, Inc.的全球首席财务官。2002年她加入DJO Global, Inc.。加入DJO Global, Inc.之前，她担任其他公共和私人公司的首席财务官。在她的职业生涯的早期，她担任Ernst & Young LLP的高级审计和会计专业人才。她目前担任Consonance Capital Partners（医疗投资公司）的高级顾问委员会的成员并且是 RF Surgical Systems, Inc.的董事会成员以及其审计委员会主席。从2007年到2010年7月被C. R. Bard, Inc.收购之前，她担任SenoRx, Inc.的董事会的成员。她是加州注册会计师并且是被the San Diego Business Journal认证的2009年和2010年年度首席财务官。她获得San Diego State University的工商管理会计学士学位。
Vickie Capps,has served as a member of Board of Directors since March 2021. Ms. Capps has also served as a member of the board of directors of Amedisys, Inc., a public healthcare company, since October 2019, and is the Chair of its audit committee and a member of its compensation committee. Ms. Capps has also served as a member of the board of directors of Orthofix Medical, Inc., a public medical technology company, since March 2025. In addition, Ms. Capps serves as a member of the boards of directors of Enable Injections, Inc. and Breg, Inc., both private medical device companies, a member of the senior advisory board of Consonance Capital Partners, a healthcare investment firm, and is also a member of the board of directors of the San Diego State University Research Foundation and a member of its audit committee and its finance and investment committee. Ms. Capps previously served on the board of directors of NuVasive, Inc., a public medical device company, from June 2015 until the closing of its merger with Globus Medical, Inc. in September 2023, of Otonomy, Inc., a public biotechnology company, from March 2014 until February 2023, of Silverback Therapeutics, Inc., a public biotechnology company, from June 2020 until the closing of its merger with ARS Pharmaceuticals, Inc. in November 2022, of Synthorx, Inc., a public biotechnology company, from April 2018 until its sale to Sanofi in January 2020, and of Connecture, Inc., a healthcare IT company, from October 2014 to April 2018. Ms. Capps has also previously served on the boards of directors of several other public and private companies, including OmniGuide Holdings, Inc., RF Surgical Systems, Inc., Eagle Rx, Inc. and SenoRx, Inc. From July 2002 to December 2013, Ms. Capps was the Chief Financial Officer of DJO Global, Inc., a medical device company. Prior to joining DJO Global, Inc., Ms. Capps served as the Chief Financial Officer of several other public and private companies. Earlier in her career, Ms. Capps was a senior audit and accounting professional at Ernst & Young LLP. Ms. Capps is a California Certified Public Accountant and was recognized as a CFO of the Year Honoree by the San Diego Business Journal in 2009 and 2010 and as a Director of the Year Honoree by the Corporate Directors Forum in 2022. Ms. Capps received a B.A. in Business Administration/Accounting from San Diego State University. - Vickie Capps自2021年3月起担任Janux Therapeutics, Inc.的董事会成员。Vickie Capps从2002年7月到2013年12月，担任DJO Global, Inc.的全球首席财务官。2002年她加入DJO Global, Inc.。加入DJO Global, Inc.之前，她担任其他公共和私人公司的首席财务官。在她的职业生涯的早期，她担任Ernst & Young LLP的高级审计和会计专业人才。她目前担任Consonance Capital Partners（医疗投资公司）的高级顾问委员会的成员并且是 RF Surgical Systems, Inc.的董事会成员以及其审计委员会主席。从2007年到2010年7月被C. R. Bard, Inc.收购之前，她担任SenoRx, Inc.的董事会的成员。她是加州注册会计师并且是被the San Diego Business Journal认证的2009年和2010年年度首席财务官。她获得San Diego State University的工商管理会计学士学位。
- Vickie Capps,has served as a member of Board of Directors since March 2021. Ms. Capps has also served as a member of the board of directors of Amedisys, Inc., a public healthcare company, since October 2019, and is the Chair of its audit committee and a member of its compensation committee. Ms. Capps has also served as a member of the board of directors of Orthofix Medical, Inc., a public medical technology company, since March 2025. In addition, Ms. Capps serves as a member of the boards of directors of Enable Injections, Inc. and Breg, Inc., both private medical device companies, a member of the senior advisory board of Consonance Capital Partners, a healthcare investment firm, and is also a member of the board of directors of the San Diego State University Research Foundation and a member of its audit committee and its finance and investment committee. Ms. Capps previously served on the board of directors of NuVasive, Inc., a public medical device company, from June 2015 until the closing of its merger with Globus Medical, Inc. in September 2023, of Otonomy, Inc., a public biotechnology company, from March 2014 until February 2023, of Silverback Therapeutics, Inc., a public biotechnology company, from June 2020 until the closing of its merger with ARS Pharmaceuticals, Inc. in November 2022, of Synthorx, Inc., a public biotechnology company, from April 2018 until its sale to Sanofi in January 2020, and of Connecture, Inc., a healthcare IT company, from October 2014 to April 2018. Ms. Capps has also previously served on the boards of directors of several other public and private companies, including OmniGuide Holdings, Inc., RF Surgical Systems, Inc., Eagle Rx, Inc. and SenoRx, Inc. From July 2002 to December 2013, Ms. Capps was the Chief Financial Officer of DJO Global, Inc., a medical device company. Prior to joining DJO Global, Inc., Ms. Capps served as the Chief Financial Officer of several other public and private companies. Earlier in her career, Ms. Capps was a senior audit and accounting professional at Ernst & Young LLP. Ms. Capps is a California Certified Public Accountant and was recognized as a CFO of the Year Honoree by the San Diego Business Journal in 2009 and 2010 and as a Director of the Year Honoree by the Corporate Directors Forum in 2022. Ms. Capps received a B.A. in Business Administration/Accounting from San Diego State University.
- Floyd Romesberg
-
Floyd Romesberg是我们的科学创始人，自2014年1月以来一直担任我们的董事会成员。任职Synthorx公司之前，他曾担任RQX Pharmaceuticals公司（2010年至2013年被Genentech，Inc.公司收购）、Achaogen公司（2005年至2011年被Achaogen公司收购）的科学联合创始人兼顾问。Romesberg博士于2014年被任命为TSRI的化学教授。在被任命为教授之前，Romesberg博士于1998年至2006年担任助理教授，并于2006年至2014年担任副教授。Romesberg博士的工作已经在150多份同行评审的出版物中进行了描述，并得到了美国国家卫生研究院，国家科学基金会和海军研究室的资助。Romesberg博士在加州大学伯克利分校（University of California，Berkeley）进行博士后培训。他在康奈尔大学（Cornell University）获得物理有机化学博士学位，在康奈尔大学（Cornell）获得化学硕士学位，在俄亥俄州立大学（Ohio State University）获得化学学士学位。
Floyd Romesberg is our Scientific Founder and has served as a member of our board of directors since January 2014. Prior to Synthorx, he served as the Scientific Co-Founder and a Consultant for RQx Pharmaceuticals, Inc. acquired by Genentech, Inc., from 2010 to 2013 and Achaogen Inc., from 2005 to 2011. Dr. Romesberg was appointed as a Professor of chemistry at TSRI in 2014. Prior to being appointed as a Professor, Dr. Romesberg was an Assistant Professor from 1998 to 2006 and an Associate Professor from 2006 to 2014. Dr. Romesberg’s work has been described in more than 150 peer-reviewed publications and has been funded by the National Institutes of Health, National Science Foundation, and Office of Naval Research. Dr. Romesberg performed his postdoctoral training at the University of California, Berkeley. He received a Ph.D. in physical organic chemistry from Cornell University, a M.S. in chemistry from Cornell and a B.S. in chemistry from The Ohio State University. - Floyd Romesberg是我们的科学创始人，自2014年1月以来一直担任我们的董事会成员。任职Synthorx公司之前，他曾担任RQX Pharmaceuticals公司（2010年至2013年被Genentech，Inc.公司收购）、Achaogen公司（2005年至2011年被Achaogen公司收购）的科学联合创始人兼顾问。Romesberg博士于2014年被任命为TSRI的化学教授。在被任命为教授之前，Romesberg博士于1998年至2006年担任助理教授，并于2006年至2014年担任副教授。Romesberg博士的工作已经在150多份同行评审的出版物中进行了描述，并得到了美国国家卫生研究院，国家科学基金会和海军研究室的资助。Romesberg博士在加州大学伯克利分校（University of California，Berkeley）进行博士后培训。他在康奈尔大学（Cornell University）获得物理有机化学博士学位，在康奈尔大学（Cornell）获得化学硕士学位，在俄亥俄州立大学（Ohio State University）获得化学学士学位。
- Floyd Romesberg is our Scientific Founder and has served as a member of our board of directors since January 2014. Prior to Synthorx, he served as the Scientific Co-Founder and a Consultant for RQx Pharmaceuticals, Inc. acquired by Genentech, Inc., from 2010 to 2013 and Achaogen Inc., from 2005 to 2011. Dr. Romesberg was appointed as a Professor of chemistry at TSRI in 2014. Prior to being appointed as a Professor, Dr. Romesberg was an Assistant Professor from 1998 to 2006 and an Associate Professor from 2006 to 2014. Dr. Romesberg’s work has been described in more than 150 peer-reviewed publications and has been funded by the National Institutes of Health, National Science Foundation, and Office of Naval Research. Dr. Romesberg performed his postdoctoral training at the University of California, Berkeley. He received a Ph.D. in physical organic chemistry from Cornell University, a M.S. in chemistry from Cornell and a B.S. in chemistry from The Ohio State University.
- Jay Lichter
-
Jay Lichter自2017年6月起担任Janux Therapeutics, Inc.的董事会成员。Jay Lichter是一个博士，自2010年12月，起出任公司董事会成员，目前担任董事会主席。他是一位经验丰富的生物技术和制药业务的执行，拥有超过25年科学研究和商业开发管理经验。自2007年以来，Lichter博士担任Avalon Ventures的管理董事，Avalon Ventures是一家早期的专注于信息技术和生命科学的风险投资基金。他的角色要求他领导Avalon的投资业务，并担任Afraxis公司，、Carolus Therapeutics公司、 Otonomy 公司、 ReVision Therapeutics公司 以及 Zacharon Pharmaceuticals公司的董事兼首席执行官，所有这些都是私营的生物技术公司。他还领导Avalon 在私营企业股份有限公司方面的投资，并担任Sova PharmaceuticalS公司，Avelas Biosciences公司， COI Pharmaceuticals 公司以及Sitari Pharmaceuticals Corpavelas 公司的董事会。Lichter博士在伊利诺伊大学（University of Illinois）生化博士学位和学士学位。他还在耶鲁大学和杜邦公司默克制药公司做了博士后。
Jay Lichter has served on our board of directors since June 2017. Dr. Lichter has served on the board of directors of Otonomy, Inc., a public biopharmaceutical company, since May 2008 and as Chairman of the board of directors since August 2015. Dr. Lichter previously served as the Chief Executive Officer from Otonomy's inception until November 2010. Dr. Lichter is currently chief executive officer of Avelas BioSciences and Fortis, both private biotechnology companies. Since 2007 Dr. Lichter has been a managing director at Avalon Ventures, an early-stage venture capital fund focused on information technology and life sciences. In that role, he led Avalon's investments in public companies Synthorx, Inc., a biopharmaceutical company acquired by Sanofi in January 2020 and Aratana Therapeutics, Inc., a pet therapeutics company, and served as a director and chief executive officer for several privately-held biotechnology companies. He previously served on the board of directors of Aratana Therapeutics, Inc. from December 2010 to August 2015 and on the board of directors of Synthorx, Inc. from February 2014 until its sale to Sanofi in January 2020. Dr. Lichter received a Bachelor's degree from the University of Illinois at Urbana-Champaign and a Ph.D. in biochemistry from the University of Illinois at Chicago. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company. - Jay Lichter自2017年6月起担任Janux Therapeutics, Inc.的董事会成员。Jay Lichter是一个博士，自2010年12月，起出任公司董事会成员，目前担任董事会主席。他是一位经验丰富的生物技术和制药业务的执行，拥有超过25年科学研究和商业开发管理经验。自2007年以来，Lichter博士担任Avalon Ventures的管理董事，Avalon Ventures是一家早期的专注于信息技术和生命科学的风险投资基金。他的角色要求他领导Avalon的投资业务，并担任Afraxis公司，、Carolus Therapeutics公司、 Otonomy 公司、 ReVision Therapeutics公司 以及 Zacharon Pharmaceuticals公司的董事兼首席执行官，所有这些都是私营的生物技术公司。他还领导Avalon 在私营企业股份有限公司方面的投资，并担任Sova PharmaceuticalS公司，Avelas Biosciences公司， COI Pharmaceuticals 公司以及Sitari Pharmaceuticals Corpavelas 公司的董事会。Lichter博士在伊利诺伊大学（University of Illinois）生化博士学位和学士学位。他还在耶鲁大学和杜邦公司默克制药公司做了博士后。
- Jay Lichter has served on our board of directors since June 2017. Dr. Lichter has served on the board of directors of Otonomy, Inc., a public biopharmaceutical company, since May 2008 and as Chairman of the board of directors since August 2015. Dr. Lichter previously served as the Chief Executive Officer from Otonomy's inception until November 2010. Dr. Lichter is currently chief executive officer of Avelas BioSciences and Fortis, both private biotechnology companies. Since 2007 Dr. Lichter has been a managing director at Avalon Ventures, an early-stage venture capital fund focused on information technology and life sciences. In that role, he led Avalon's investments in public companies Synthorx, Inc., a biopharmaceutical company acquired by Sanofi in January 2020 and Aratana Therapeutics, Inc., a pet therapeutics company, and served as a director and chief executive officer for several privately-held biotechnology companies. He previously served on the board of directors of Aratana Therapeutics, Inc. from December 2010 to August 2015 and on the board of directors of Synthorx, Inc. from February 2014 until its sale to Sanofi in January 2020. Dr. Lichter received a Bachelor's degree from the University of Illinois at Urbana-Champaign and a Ph.D. in biochemistry from the University of Illinois at Chicago. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company.
- Peter Thompson
-
Peter Thompson，曾担任Corvus Pharmaceuticals， Inc.的成员。自2014年11月担任董事会成员，并共同创立了公司。Thompson博士是投资公司OrbiMed Advisors LLC的成员。Thompson博士目前担任ARS Pharmaceuticals， Inc.（原Silverback Therapeutics， Inc.）， Edgewise Therapeutics, Inc.和Sionna Therapeutics， Inc.以及几家私人公司的董事会成员。此前，Thompson博士担任Alpine Immune Sciences， Inc.、分贝治疗公司、Janux Therapeutics， Inc.、PMV Pharmaceuticals, Inc.和precpretherapeutics Inc.的董事会成员。Thompson博士此前还曾担任Trubion Pharmaceuticals， Inc.、Chiron Corporation和Becton， Dickinson and Company的执行领导职务。Thompson博士是华盛顿大学神经外科副教授。此外，Thompson博士拥有多项专利，是董事会认证的内科医生和肿瘤学家。他持有Brown大学的分子生物学和数学学士学位，以及Brown大学Medical School的医学博士学位。
Peter Thompson,is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson is also the Chairman of Terremoto Biosciences, Inc., a biotechnology company developing targeted therapeutics, since August 2024, where he previously served as President and Chief Executive Officer from August 2021 to August 2024. Dr. Thompson previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc., a biopharmaceutical company targeting glia-mediated pathways from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC, a drug discovery and development company from August 2021 to December 2022. Dr. Thompson currently serves on the boards of directors of several public companies, including Sionna Therapeutics, Inc. (since February 2022), Corvus Pharmaceuticals, Inc. (since November 2014), and ARS Pharmaceuticals Inc. (since April 2016). Dr. Thompson has previously served on the boards of directors of Alpine Immune Sciences, Inc., Janux Therapeutics, Inc., Decibel Therapeutics, Inc., Adaptimmune Therapeutics PLC, Principia Biopharma Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics, Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson received a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. - Peter Thompson，曾担任Corvus Pharmaceuticals， Inc.的成员。自2014年11月担任董事会成员，并共同创立了公司。Thompson博士是投资公司OrbiMed Advisors LLC的成员。Thompson博士目前担任ARS Pharmaceuticals， Inc.（原Silverback Therapeutics， Inc.）， Edgewise Therapeutics, Inc.和Sionna Therapeutics， Inc.以及几家私人公司的董事会成员。此前，Thompson博士担任Alpine Immune Sciences， Inc.、分贝治疗公司、Janux Therapeutics， Inc.、PMV Pharmaceuticals, Inc.和precpretherapeutics Inc.的董事会成员。Thompson博士此前还曾担任Trubion Pharmaceuticals， Inc.、Chiron Corporation和Becton， Dickinson and Company的执行领导职务。Thompson博士是华盛顿大学神经外科副教授。此外，Thompson博士拥有多项专利，是董事会认证的内科医生和肿瘤学家。他持有Brown大学的分子生物学和数学学士学位，以及Brown大学Medical School的医学博士学位。
- Peter Thompson,is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson is also the Chairman of Terremoto Biosciences, Inc., a biotechnology company developing targeted therapeutics, since August 2024, where he previously served as President and Chief Executive Officer from August 2021 to August 2024. Dr. Thompson previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc., a biopharmaceutical company targeting glia-mediated pathways from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC, a drug discovery and development company from August 2021 to December 2022. Dr. Thompson currently serves on the boards of directors of several public companies, including Sionna Therapeutics, Inc. (since February 2022), Corvus Pharmaceuticals, Inc. (since November 2014), and ARS Pharmaceuticals Inc. (since April 2016). Dr. Thompson has previously served on the boards of directors of Alpine Immune Sciences, Inc., Janux Therapeutics, Inc., Decibel Therapeutics, Inc., Adaptimmune Therapeutics PLC, Principia Biopharma Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics, Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson received a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
- Laura Shawver
-
Laura Shawver自2020年4月以来一直担任我们的首席执行官兼董事会成员。Shawver博士还自2017年3月起担任RelayTherapeutics，Inc.董事会成员，自2020年3月起担任Nkarta，Inc.董事会成员。此前，Shawver博士曾于2017年11月至2020年1月被赛诺菲收购期间担任Synthorx，Inc.的总裁兼首席执行官兼董事会成员。2011年9月至2018年4月，她担任Cleave Biosciences的首席执行官兼董事会成员。从2010年10月到2011年8月，她曾担任5AM Ventures公司的常驻企业家，此前曾任职Phenomix Science公司、Sugen公司、Berlex Biosciences公司（原名Triton Biosciences公司）。Shawver博士拥有爱荷华大学（University of Iowa）的微生物学学士学位和药理学博士学位。
Laura Shawver,has served as a member of board of directors since March 2017. Dr. Shawver will not stand for re-election as a Class II director at the Annual Meeting. Since September 2022, Dr. Shawver has served as the President and Chief Executive Officer of Capstan Therapeutics, Inc., a privately held biotechnology company, and a member of its board of directors. From April 2020 until its acquisition by ARS Pharmaceuticals, Inc. in 2022, Dr. Shawver was President and Chief Executive Officer of Silverback Therapeutics, Inc., a publicly traded biotechnology company. Dr. Shawver has served as a member of the board of directors of ARS Pharmaceuticals, Inc. since November 2022. From November 2017 until its acquisition by Sanofi, Inc. in January 2020, Dr. Shawver served as the President and Chief Executive Officer of Synthorx, Inc., a publicly traded biotechnology company, and as a member of its board of directors. From March 2020 to June 2023, Dr. Shawver also served as a member of the board of directors of publicly-traded biotechnology company, Nkarta, Inc. She also serves as a member of the board of directors of Bright Peak Therapeutics and Dovetail Therapeutics, both of which are privately held biotechnology companies. Dr. Shawver previously served as Chief Executive Officer of Cleave Therapeutics, Inc., Entrepreneur in Residence for 5AM Ventures, Chief Executive Officer of Phenomix Corporation and President of Sugen, Inc. Dr. Shawver holds a B.S. in microbiology and a Ph.D. in pharmacology from the University of Iowa. Dr. Shawver's extensive experience leading companies in the pharmaceutical industry qualifies her to serve on board of directors. - Laura Shawver自2020年4月以来一直担任我们的首席执行官兼董事会成员。Shawver博士还自2017年3月起担任RelayTherapeutics，Inc.董事会成员，自2020年3月起担任Nkarta，Inc.董事会成员。此前，Shawver博士曾于2017年11月至2020年1月被赛诺菲收购期间担任Synthorx，Inc.的总裁兼首席执行官兼董事会成员。2011年9月至2018年4月，她担任Cleave Biosciences的首席执行官兼董事会成员。从2010年10月到2011年8月，她曾担任5AM Ventures公司的常驻企业家，此前曾任职Phenomix Science公司、Sugen公司、Berlex Biosciences公司（原名Triton Biosciences公司）。Shawver博士拥有爱荷华大学（University of Iowa）的微生物学学士学位和药理学博士学位。
- Laura Shawver,has served as a member of board of directors since March 2017. Dr. Shawver will not stand for re-election as a Class II director at the Annual Meeting. Since September 2022, Dr. Shawver has served as the President and Chief Executive Officer of Capstan Therapeutics, Inc., a privately held biotechnology company, and a member of its board of directors. From April 2020 until its acquisition by ARS Pharmaceuticals, Inc. in 2022, Dr. Shawver was President and Chief Executive Officer of Silverback Therapeutics, Inc., a publicly traded biotechnology company. Dr. Shawver has served as a member of the board of directors of ARS Pharmaceuticals, Inc. since November 2022. From November 2017 until its acquisition by Sanofi, Inc. in January 2020, Dr. Shawver served as the President and Chief Executive Officer of Synthorx, Inc., a publicly traded biotechnology company, and as a member of its board of directors. From March 2020 to June 2023, Dr. Shawver also served as a member of the board of directors of publicly-traded biotechnology company, Nkarta, Inc. She also serves as a member of the board of directors of Bright Peak Therapeutics and Dovetail Therapeutics, both of which are privately held biotechnology companies. Dr. Shawver previously served as Chief Executive Officer of Cleave Therapeutics, Inc., Entrepreneur in Residence for 5AM Ventures, Chief Executive Officer of Phenomix Corporation and President of Sugen, Inc. Dr. Shawver holds a B.S. in microbiology and a Ph.D. in pharmacology from the University of Iowa. Dr. Shawver's extensive experience leading companies in the pharmaceutical industry qualifies her to serve on board of directors.
- Pratik Shah
-
2013年10月以来，Pratik Shah 担任Auspex Pharmaceuticals, Inc.的总裁兼首席执行官。2007年6月以来，他是Auspex Pharmaceuticals, Inc.董事会的成员。从2008年9月到2013年10月他担任Auspex Pharmaceuticals, Inc.董事会主席。自2004年以来他是 Thomas, McNerney & Partners 风险资本公司的合伙人。加入Thomas，McNerney & Partners之前，他创办了Kalypsys公司，一家私人临床阶段制药公司，从2001年到2004年，他担任首席商务官负责公司的总体战略、业务发展和运营。创办Kalypsys之前，从1999年到2001年，他是McKinsey & Company工作，一家咨询公司，他负责生物技术和风险资本项目。加入McKinsey & Company之前，他创办NephRx Corporation，主攻研究肾脏疾病的治疗蛋白质的一家新创公司，从1997年到1999年，在那里他担任业务副总裁。除了担任Auspex Pharmaceuticals, Inc.的董事外，他当前在Ocera Therapeutics担任董事，一家上市临床阶段生物制药公司。以及其他私人公司的董事：Cebix Incorporated 和 SGB。他从加州大学欧文分校获得生物科学学士学位，从芝加哥大学获得生物化学和分子生物学博士学位和金融MBA。
Pratik Shah,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors and Ars Pharmaceuticals, Inc. Chair since the closing of the Merger in November 2022. Dr. Shah previously served on the board of directors of Private ARS Pharma from April 2016 to November 2022 and was appointed as its first Chair of the board of directors in September 2018. Dr. Shah has also served as the Executive Chair and member of the board of directors for Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company, since December 2017, and as President of Marlinspike Group, LLC, since August 2018, and of Marlinspike Group Inc. from June 2015 to October 2020. Dr. Shah served as the Chair of the board of directors of Synthorx, Inc. (formerly Nasdaq: THOR), a clinical-stage biotechnology company, from October 2018 until its acquisition by Sanofi S.A. in January 2020. Dr. Shah also served as the President and Chief Executive Officer and Chair of the board of directors of Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX), biopharmaceutical company, from October 2013 until its acquisition by Teva Pharmaceutical Industries Ltd. in May 2015. From 2004 to 2014 he was a partner at Thomas, McNerney & Partners, a healthcare venture capital firm. Dr. Shah holds a B.S in Biological Sciences from the University of California at Irvine and a Ph.D. in Biochemistry and Molecular Biology and an M.B.A. in Finance, both from the University of Chicago. - 2013年10月以来，Pratik Shah 担任Auspex Pharmaceuticals, Inc.的总裁兼首席执行官。2007年6月以来，他是Auspex Pharmaceuticals, Inc.董事会的成员。从2008年9月到2013年10月他担任Auspex Pharmaceuticals, Inc.董事会主席。自2004年以来他是 Thomas, McNerney & Partners 风险资本公司的合伙人。加入Thomas，McNerney & Partners之前，他创办了Kalypsys公司，一家私人临床阶段制药公司，从2001年到2004年，他担任首席商务官负责公司的总体战略、业务发展和运营。创办Kalypsys之前，从1999年到2001年，他是McKinsey & Company工作，一家咨询公司，他负责生物技术和风险资本项目。加入McKinsey & Company之前，他创办NephRx Corporation，主攻研究肾脏疾病的治疗蛋白质的一家新创公司，从1997年到1999年，在那里他担任业务副总裁。除了担任Auspex Pharmaceuticals, Inc.的董事外，他当前在Ocera Therapeutics担任董事，一家上市临床阶段生物制药公司。以及其他私人公司的董事：Cebix Incorporated 和 SGB。他从加州大学欧文分校获得生物科学学士学位，从芝加哥大学获得生物化学和分子生物学博士学位和金融MBA。
- Pratik Shah,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors and Ars Pharmaceuticals, Inc. Chair since the closing of the Merger in November 2022. Dr. Shah previously served on the board of directors of Private ARS Pharma from April 2016 to November 2022 and was appointed as its first Chair of the board of directors in September 2018. Dr. Shah has also served as the Executive Chair and member of the board of directors for Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company, since December 2017, and as President of Marlinspike Group, LLC, since August 2018, and of Marlinspike Group Inc. from June 2015 to October 2020. Dr. Shah served as the Chair of the board of directors of Synthorx, Inc. (formerly Nasdaq: THOR), a clinical-stage biotechnology company, from October 2018 until its acquisition by Sanofi S.A. in January 2020. Dr. Shah also served as the President and Chief Executive Officer and Chair of the board of directors of Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX), biopharmaceutical company, from October 2013 until its acquisition by Teva Pharmaceutical Industries Ltd. in May 2015. From 2004 to 2014 he was a partner at Thomas, McNerney & Partners, a healthcare venture capital firm. Dr. Shah holds a B.S in Biological Sciences from the University of California at Irvine and a Ph.D. in Biochemistry and Molecular Biology and an M.B.A. in Finance, both from the University of Chicago.
- Peter Kolchinsky
-
Peter Kolchinsky，他是一名博士，自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月，他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃，投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍，并在American Fertility Association公司担任董事。目前，他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院（National Academies of Sciences）的全球科技委员会任职。他在哈佛大学（Harvard University）获得病毒学博士学位，并在美国康乃尔大学（Cornell University）获得学士学位。
Peter Kolchinsky,has served on Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Kolchinsky previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Dr. Kolchinsky has more than 20 years of experience in healthcare investing and is the Founder of and a Managing Partner at RA Capital Management, L.P. RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, diagnostics and research tools. Dr. Kolchinsky has also served on the boards of directors of ICOSAVAX, Inc. (Nasdaq: ICVX), a vaccine development company, since March 2021, and WAVE Life Sciences, Ltd. (Nasdaq: WVE), a biotechnology company focused on delivering therapies for patients with serious, genetically-defined diseases, since January 2015, in addition to a number of private companies. Dr. Kolchinsky was previously a member of the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), from July 2013 to December 2019, Forma Therapeutics Holdings, Inc. (formerly Nasdaq: FMTX), from December 2019 to October 2022 and Synthorx, Inc. (formerly Nasdaq: THOR), from May 2018 to January 2020, all public pharmaceutical companies. Dr. Kolchinsky also served on the Board of Global Science and Technology for the National Academy of Sciences, and is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup". He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Dr. Kolchinsky holds a BA from Cornell University and a Ph.D. in Virology from Harvard University. - Peter Kolchinsky，他是一名博士，自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月，他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃，投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍，并在American Fertility Association公司担任董事。目前，他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院（National Academies of Sciences）的全球科技委员会任职。他在哈佛大学（Harvard University）获得病毒学博士学位，并在美国康乃尔大学（Cornell University）获得学士学位。
- Peter Kolchinsky,has served on Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Kolchinsky previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Dr. Kolchinsky has more than 20 years of experience in healthcare investing and is the Founder of and a Managing Partner at RA Capital Management, L.P. RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, diagnostics and research tools. Dr. Kolchinsky has also served on the boards of directors of ICOSAVAX, Inc. (Nasdaq: ICVX), a vaccine development company, since March 2021, and WAVE Life Sciences, Ltd. (Nasdaq: WVE), a biotechnology company focused on delivering therapies for patients with serious, genetically-defined diseases, since January 2015, in addition to a number of private companies. Dr. Kolchinsky was previously a member of the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), from July 2013 to December 2019, Forma Therapeutics Holdings, Inc. (formerly Nasdaq: FMTX), from December 2019 to October 2022 and Synthorx, Inc. (formerly Nasdaq: THOR), from May 2018 to January 2020, all public pharmaceutical companies. Dr. Kolchinsky also served on the Board of Global Science and Technology for the National Academy of Sciences, and is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup". He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Dr. Kolchinsky holds a BA from Cornell University and a Ph.D. in Virology from Harvard University.
高管简历
中英对照 | 中文 | 英文- Joseph Leveque
Joseph Leveque自2018年7月起担任首席医疗官。在加入Synthorx之前，Leveque博士曾于2017年10月至2018年6月担任ARMO Biosciences的首席医疗官，在那里他发起，概念化，设计和实施了癌症疗法的临床研究和开发计划。Leveque博士还于2015年9月至2017年9月担任EMD Serono的首席医疗官。Leveque博士于2011年9月至2015年9月担任百时美施贵宝（Bristol-Myers Squibb）的Vice President兼美国医疗肿瘤学主管，参与了第一代IO Therapeutics的开发和商业化。在任职Bristol-Myers Squibb之前，Leveque博士于2009年7月至2011年9月担任Onyx Pharmaceuticals或Onyx的医疗和科学事务Vice President。加入Onyx公司之前，他曾于2007年5月至2009年7月担任Cephalon，Inc.肿瘤医疗和科学事务Vice President，并于2005年2月至2007年5月担任Amgen公司的医疗主管，在那里他曾从事实体瘤和血液系统恶性肿瘤的几个治疗项目。Leveque博士在圣克拉拉大学（Santa Clara University）获得生物学学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得工商管理硕士学位，在德克萨斯大学医学院（University of Texas Medical School）获得医学博士学位。
Joseph Leveque has served as our Chief Medical Officer since July 2018. Prior to joining Synthorx, Dr. Leveque served as Chief Medical Officer of ARMO BioSciences, where he originated, conceptualized, designed and implemented clinical studies and development plans for cancer therapeutics, from October 2017 to June 2018. Dr. Leveque also served as Chief Medical Officer of EMD Serono, from September 2015 to September 2017. Dr. Leveque served as Vice President and head of U.S. Medical Oncology at Bristol-Myers Squibb, from September 2011 to September 2015 where he was involved in the development and commercialization of the first generation of IO therapeutics. Before his role at Bristol-Myers Squibb, Dr. Leveque was the Vice President of Medical and Scientific Affairs at Onyx Pharmaceuticals, or Onyx, from July 2009 to September 2011. Before joining Onyx, he served as Vice President of Oncology Medical and Scientific Affairs at Cephalon, Inc., from May 2007 to July 2009 and as medical director at Amgen, Inc., from February 2005 to May 2007 where he worked on several therapeutic programs for solid tumor and hematological malignancies. Dr. Leveque obtained a Bachelor’s degree in Biology from Santa Clara University, a MBA from The Wharton School at the University of Pennsylvania and a M.D. from the University of Texas Medical School.- Joseph Leveque自2018年7月起担任首席医疗官。在加入Synthorx之前，Leveque博士曾于2017年10月至2018年6月担任ARMO Biosciences的首席医疗官，在那里他发起，概念化，设计和实施了癌症疗法的临床研究和开发计划。Leveque博士还于2015年9月至2017年9月担任EMD Serono的首席医疗官。Leveque博士于2011年9月至2015年9月担任百时美施贵宝（Bristol-Myers Squibb）的Vice President兼美国医疗肿瘤学主管，参与了第一代IO Therapeutics的开发和商业化。在任职Bristol-Myers Squibb之前，Leveque博士于2009年7月至2011年9月担任Onyx Pharmaceuticals或Onyx的医疗和科学事务Vice President。加入Onyx公司之前，他曾于2007年5月至2009年7月担任Cephalon，Inc.肿瘤医疗和科学事务Vice President，并于2005年2月至2007年5月担任Amgen公司的医疗主管，在那里他曾从事实体瘤和血液系统恶性肿瘤的几个治疗项目。Leveque博士在圣克拉拉大学（Santa Clara University）获得生物学学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得工商管理硕士学位，在德克萨斯大学医学院（University of Texas Medical School）获得医学博士学位。
- Joseph Leveque has served as our Chief Medical Officer since July 2018. Prior to joining Synthorx, Dr. Leveque served as Chief Medical Officer of ARMO BioSciences, where he originated, conceptualized, designed and implemented clinical studies and development plans for cancer therapeutics, from October 2017 to June 2018. Dr. Leveque also served as Chief Medical Officer of EMD Serono, from September 2015 to September 2017. Dr. Leveque served as Vice President and head of U.S. Medical Oncology at Bristol-Myers Squibb, from September 2011 to September 2015 where he was involved in the development and commercialization of the first generation of IO therapeutics. Before his role at Bristol-Myers Squibb, Dr. Leveque was the Vice President of Medical and Scientific Affairs at Onyx Pharmaceuticals, or Onyx, from July 2009 to September 2011. Before joining Onyx, he served as Vice President of Oncology Medical and Scientific Affairs at Cephalon, Inc., from May 2007 to July 2009 and as medical director at Amgen, Inc., from February 2005 to May 2007 where he worked on several therapeutic programs for solid tumor and hematological malignancies. Dr. Leveque obtained a Bachelor’s degree in Biology from Santa Clara University, a MBA from The Wharton School at the University of Pennsylvania and a M.D. from the University of Texas Medical School.
- Tighe Reardon
Tighe Reardon自2017年6月成立以来一直担任代理首席财务官。此前，Reardon先生曾担任Synthorx，Inc.的代理首席财务官，Synthorx，Inc，一家公共生物制药公司，从2015年11月至2020年1月出售给赛诺菲。里尔登先生自2014年6月起担任Avalon Ventures的首席财务官。作为他在Avalon的职责之一，他为多家Avalon投资组合公司提供首席财务官服务，并是多家Avalon投资组合公司的董事会成员投资组合公司，包括Adanate，Inc.，AristaMD，Inc.和COI。在加入Avalon之前，Reardon先生于2008年4月至2014年6月担任DJO Global，Inc.税务和财政部高级副总裁。Reardon先生的职业生涯始于Arthur Andersen LLP.里尔顿先生在圣地亚哥州立大学获得会计学士学位和税务硕士学位。他是加利福尼亚州的注册会计师。
Tighe Reardon has served as the Acting Chief Financial Officer since our inception in June 2017. Previously, Mr. Reardon served as the Acting Chief Financial Officer for Synthorx, Inc., a public biopharmaceutical company, from November 2015 until its sale to Sanofi in January 2020. Mr. Reardon has also served as Chief Financial Officer of Avalon Ventures since June 2014. As part of his responsibilities at Avalon he provides Chief Financial Officer services to a number of Avalon portfolio companies and is a member of the board of directors for a number of Avalon portfolio companies, including among others, Adanate, Inc., AristaMD, Inc. and COI. Prior to joining Avalon, Mr. Reardon was the Senior Vice President of Tax and Treasury at DJO Global, Inc., from April 2008 to June 2014. Mr. Reardon began his career at Arthur Andersen LLP. Mr. Reardon received a B.S. in accounting and an M.S. in taxation from San Diego State University. He is a Certified Public Accountant in the State of California.- Tighe Reardon自2017年6月成立以来一直担任代理首席财务官。此前，Reardon先生曾担任Synthorx，Inc.的代理首席财务官，Synthorx，Inc，一家公共生物制药公司，从2015年11月至2020年1月出售给赛诺菲。里尔登先生自2014年6月起担任Avalon Ventures的首席财务官。作为他在Avalon的职责之一，他为多家Avalon投资组合公司提供首席财务官服务，并是多家Avalon投资组合公司的董事会成员投资组合公司，包括Adanate，Inc.，AristaMD，Inc.和COI。在加入Avalon之前，Reardon先生于2008年4月至2014年6月担任DJO Global，Inc.税务和财政部高级副总裁。Reardon先生的职业生涯始于Arthur Andersen LLP.里尔顿先生在圣地亚哥州立大学获得会计学士学位和税务硕士学位。他是加利福尼亚州的注册会计师。
- Tighe Reardon has served as the Acting Chief Financial Officer since our inception in June 2017. Previously, Mr. Reardon served as the Acting Chief Financial Officer for Synthorx, Inc., a public biopharmaceutical company, from November 2015 until its sale to Sanofi in January 2020. Mr. Reardon has also served as Chief Financial Officer of Avalon Ventures since June 2014. As part of his responsibilities at Avalon he provides Chief Financial Officer services to a number of Avalon portfolio companies and is a member of the board of directors for a number of Avalon portfolio companies, including among others, Adanate, Inc., AristaMD, Inc. and COI. Prior to joining Avalon, Mr. Reardon was the Senior Vice President of Tax and Treasury at DJO Global, Inc., from April 2008 to June 2014. Mr. Reardon began his career at Arthur Andersen LLP. Mr. Reardon received a B.S. in accounting and an M.S. in taxation from San Diego State University. He is a Certified Public Accountant in the State of California.
- Marcos Milla
Marcos Milla自2018年4月起担任我们的首席科学官。在成为我们的首席科学官之前，米拉博士自2017年8月起担任我们的研究高级副总裁。在加入Synthorx之前，米拉博士于2016年5月至2017年7月担任Adaptive Biotechnologies Corporation的发现主管。任职Adaptive Biotechnologies公司之前，Milla博士曾担任Janssen Pharmaceuticals，Inc.的多种职务，包括发现科学高级董事（从2014年11月到2016年4月）、发现科学董事（从2014年4月到2014年11月）和免疫学科学董事。从2013年3月到2014年3月，他曾领导团队专注于小分子药物和疾病特征分析和筛选的新方法的开发。Milla’；博士在药物发现方面的经验横跨自身免疫和炎症，神经科学和疼痛以及IO领域，他在药物化学和网络药理学方面拥有专业知识。他也曾担任the University of Pennsylvania的Perelman School of Medicine的学术职务。Milla博士毕业于秘鲁利马Universidad Peruana Cayetano Heredia的B.S.和Saint Louis University的细胞与分子生物学博士学位。他在麻省理工学院（MIT）和杜克大学（Duke University）接受博士后培训，分别担任简·科芬·柴尔德（Jane Coffin Childs）研究员和博士。
Marcos Milla has served as our Chief Scientific Officer since April 2018. Before becoming our Chief Scientific Officer, Dr. Milla served as our Senior Vice President of Research, since August 2017. Prior to joining Synthorx, Dr. Milla served as Head of Discovery at Adaptive Biotechnologies Corporation, from May 2016 to July 2017. Prior to his time at Adaptive Biotechnologies, Dr. Milla served in various roles at Janssen Pharmaceuticals, Inc., including as Senior Director of Discovery Sciences, from November 2014 to April 2016 Director of Discovery Sciences, from April 2014 to November 2014 and Scientific Director of Immunology, from March 2013 to March 2014 where he led teams focused on small molecule drugs and the development of novel ways of disease profiling and screening. Dr. Milla’s experience in drug discovery spans across the areas of autoimmunity and inflammation, neurosciences and pain and IO and he has expertise in medicinal chemistry and network pharmacology. He has also held academic appointments at Perelman School of Medicine at the University of Pennsylvania. Dr. Milla graduated with a B.S. from Universidad Peruana Cayetano Heredia in Lima, Peru and a Ph.D. in cell and molecular biology from Saint Louis University. He did his postdoctoral training at MIT as a Jane Coffin Childs Fellow and at Duke University.- Marcos Milla自2018年4月起担任我们的首席科学官。在成为我们的首席科学官之前，米拉博士自2017年8月起担任我们的研究高级副总裁。在加入Synthorx之前，米拉博士于2016年5月至2017年7月担任Adaptive Biotechnologies Corporation的发现主管。任职Adaptive Biotechnologies公司之前，Milla博士曾担任Janssen Pharmaceuticals，Inc.的多种职务，包括发现科学高级董事（从2014年11月到2016年4月）、发现科学董事（从2014年4月到2014年11月）和免疫学科学董事。从2013年3月到2014年3月，他曾领导团队专注于小分子药物和疾病特征分析和筛选的新方法的开发。Milla’；博士在药物发现方面的经验横跨自身免疫和炎症，神经科学和疼痛以及IO领域，他在药物化学和网络药理学方面拥有专业知识。他也曾担任the University of Pennsylvania的Perelman School of Medicine的学术职务。Milla博士毕业于秘鲁利马Universidad Peruana Cayetano Heredia的B.S.和Saint Louis University的细胞与分子生物学博士学位。他在麻省理工学院（MIT）和杜克大学（Duke University）接受博士后培训，分别担任简·科芬·柴尔德（Jane Coffin Childs）研究员和博士。
- Marcos Milla has served as our Chief Scientific Officer since April 2018. Before becoming our Chief Scientific Officer, Dr. Milla served as our Senior Vice President of Research, since August 2017. Prior to joining Synthorx, Dr. Milla served as Head of Discovery at Adaptive Biotechnologies Corporation, from May 2016 to July 2017. Prior to his time at Adaptive Biotechnologies, Dr. Milla served in various roles at Janssen Pharmaceuticals, Inc., including as Senior Director of Discovery Sciences, from November 2014 to April 2016 Director of Discovery Sciences, from April 2014 to November 2014 and Scientific Director of Immunology, from March 2013 to March 2014 where he led teams focused on small molecule drugs and the development of novel ways of disease profiling and screening. Dr. Milla’s experience in drug discovery spans across the areas of autoimmunity and inflammation, neurosciences and pain and IO and he has expertise in medicinal chemistry and network pharmacology. He has also held academic appointments at Perelman School of Medicine at the University of Pennsylvania. Dr. Milla graduated with a B.S. from Universidad Peruana Cayetano Heredia in Lima, Peru and a Ph.D. in cell and molecular biology from Saint Louis University. He did his postdoctoral training at MIT as a Jane Coffin Childs Fellow and at Duke University.
- Laura Shawver
Laura Shawver自2020年4月以来一直担任我们的首席执行官兼董事会成员。Shawver博士还自2017年3月起担任RelayTherapeutics，Inc.董事会成员，自2020年3月起担任Nkarta，Inc.董事会成员。此前，Shawver博士曾于2017年11月至2020年1月被赛诺菲收购期间担任Synthorx，Inc.的总裁兼首席执行官兼董事会成员。2011年9月至2018年4月，她担任Cleave Biosciences的首席执行官兼董事会成员。从2010年10月到2011年8月，她曾担任5AM Ventures公司的常驻企业家，此前曾任职Phenomix Science公司、Sugen公司、Berlex Biosciences公司（原名Triton Biosciences公司）。Shawver博士拥有爱荷华大学（University of Iowa）的微生物学学士学位和药理学博士学位。
Laura Shawver,has served as a member of board of directors since March 2017. Dr. Shawver will not stand for re-election as a Class II director at the Annual Meeting. Since September 2022, Dr. Shawver has served as the President and Chief Executive Officer of Capstan Therapeutics, Inc., a privately held biotechnology company, and a member of its board of directors. From April 2020 until its acquisition by ARS Pharmaceuticals, Inc. in 2022, Dr. Shawver was President and Chief Executive Officer of Silverback Therapeutics, Inc., a publicly traded biotechnology company. Dr. Shawver has served as a member of the board of directors of ARS Pharmaceuticals, Inc. since November 2022. From November 2017 until its acquisition by Sanofi, Inc. in January 2020, Dr. Shawver served as the President and Chief Executive Officer of Synthorx, Inc., a publicly traded biotechnology company, and as a member of its board of directors. From March 2020 to June 2023, Dr. Shawver also served as a member of the board of directors of publicly-traded biotechnology company, Nkarta, Inc. She also serves as a member of the board of directors of Bright Peak Therapeutics and Dovetail Therapeutics, both of which are privately held biotechnology companies. Dr. Shawver previously served as Chief Executive Officer of Cleave Therapeutics, Inc., Entrepreneur in Residence for 5AM Ventures, Chief Executive Officer of Phenomix Corporation and President of Sugen, Inc. Dr. Shawver holds a B.S. in microbiology and a Ph.D. in pharmacology from the University of Iowa. Dr. Shawver's extensive experience leading companies in the pharmaceutical industry qualifies her to serve on board of directors.- Laura Shawver自2020年4月以来一直担任我们的首席执行官兼董事会成员。Shawver博士还自2017年3月起担任RelayTherapeutics，Inc.董事会成员，自2020年3月起担任Nkarta，Inc.董事会成员。此前，Shawver博士曾于2017年11月至2020年1月被赛诺菲收购期间担任Synthorx，Inc.的总裁兼首席执行官兼董事会成员。2011年9月至2018年4月，她担任Cleave Biosciences的首席执行官兼董事会成员。从2010年10月到2011年8月，她曾担任5AM Ventures公司的常驻企业家，此前曾任职Phenomix Science公司、Sugen公司、Berlex Biosciences公司（原名Triton Biosciences公司）。Shawver博士拥有爱荷华大学（University of Iowa）的微生物学学士学位和药理学博士学位。
- Laura Shawver,has served as a member of board of directors since March 2017. Dr. Shawver will not stand for re-election as a Class II director at the Annual Meeting. Since September 2022, Dr. Shawver has served as the President and Chief Executive Officer of Capstan Therapeutics, Inc., a privately held biotechnology company, and a member of its board of directors. From April 2020 until its acquisition by ARS Pharmaceuticals, Inc. in 2022, Dr. Shawver was President and Chief Executive Officer of Silverback Therapeutics, Inc., a publicly traded biotechnology company. Dr. Shawver has served as a member of the board of directors of ARS Pharmaceuticals, Inc. since November 2022. From November 2017 until its acquisition by Sanofi, Inc. in January 2020, Dr. Shawver served as the President and Chief Executive Officer of Synthorx, Inc., a publicly traded biotechnology company, and as a member of its board of directors. From March 2020 to June 2023, Dr. Shawver also served as a member of the board of directors of publicly-traded biotechnology company, Nkarta, Inc. She also serves as a member of the board of directors of Bright Peak Therapeutics and Dovetail Therapeutics, both of which are privately held biotechnology companies. Dr. Shawver previously served as Chief Executive Officer of Cleave Therapeutics, Inc., Entrepreneur in Residence for 5AM Ventures, Chief Executive Officer of Phenomix Corporation and President of Sugen, Inc. Dr. Shawver holds a B.S. in microbiology and a Ph.D. in pharmacology from the University of Iowa. Dr. Shawver's extensive experience leading companies in the pharmaceutical industry qualifies her to serve on board of directors.